# Takeda Pharmaceutical Co Ltd: financial statements, quarterly

TAK · NYSE · CIK 1395064 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/tak.md) · [Financials](/companies/tak/financials.md) · [Filings](/companies/tak/filings.md) · [Insiders](/companies/tak/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tak/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2016-03-31) | period not labelled (2017-03-31) | period not labelled (2018-03-31) | FY2019 (2019-03-31) | FY2020 (2020-03-31) | FY2021 (2021-03-31) | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [451](/filings/0001395064-19-000005.md) | [319](/filings/0001395064-20-000110.md) | [295](/filings/0001395064-21-000140.md) | [702](/filings/0001395064-22-000107.md) | [638](/filings/0001395064-23-000072.md) | [966](/filings/0001395064-24-000086.md) | [850](/filings/0001395064-25-000095.md) | [534](/filings/0001395064-25-000095.md) | [458](/filings/0001395064-25-000095.md) | [385](/filings/0001395064-25-000095.md) |
| Current assets | $bn | not reported | not reported | [1,079](/filings/0001395064-19-000005.md) | [2,993](/filings/0001395064-20-000110.md) | [2,469](/filings/0001395064-21-000140.md) | [2,713](/filings/0001395064-22-000107.md) | [2,594](/filings/0001395064-23-000072.md) | [2,398](/filings/0001395064-24-000086.md) | [2,559](/filings/0001395064-25-000095.md) | [2,521](/filings/0001395064-25-000095.md) |
| Total assets | $bn | not reported | not reported | [4,106](/filings/0001395064-19-000005.md) | [13,793](/filings/0001395064-20-000110.md) | [12,821](/filings/0001395064-21-000140.md) | [12,912](/filings/0001395064-22-000107.md) | [13,178](/filings/0001395064-23-000072.md) | [13,958](/filings/0001395064-24-000086.md) | [15,109](/filings/0001395064-25-000095.md) | [14,248](/filings/0001395064-25-000095.md) |
| Current liabilities | $bn | not reported | not reported | [738](/filings/0001395064-19-000005.md) | [2,553](/filings/0001395064-20-000110.md) | [2,176](/filings/0001395064-21-000140.md) | [1,773](/filings/0001395064-22-000107.md) | [2,146](/filings/0001395064-23-000072.md) | [2,482](/filings/0001395064-24-000086.md) | [2,313](/filings/0001395064-25-000095.md) | [2,507](/filings/0001395064-25-000095.md) |
| Total liabilities | $bn | not reported | not reported | [2,089](/filings/0001395064-19-000005.md) | [8,607](/filings/0001395064-20-000110.md) | [8,094](/filings/0001395064-21-000140.md) | [7,735](/filings/0001395064-22-000107.md) | [7,494](/filings/0001395064-23-000072.md) | [7,603](/filings/0001395064-24-000086.md) | [7,835](/filings/0001395064-25-000095.md) | [7,312](/filings/0001395064-25-000095.md) |
| Shareholders' equity | $bn | [2,011](/filings/0001395064-19-000005.md) | [1,949](/filings/0001395064-20-000110.md) | [1,997](/filings/0001395064-19-000005.md) | [5,182](/filings/0001395064-20-000110.md) | [4,723](/filings/0001395064-21-000140.md) | [5,173](/filings/0001395064-22-000107.md) | [5,683](/filings/0001395064-23-000072.md) | [6,354](/filings/0001395064-24-000086.md) | [7,273](/filings/0001395064-25-000095.md) | [6,935](/filings/0001395064-25-000095.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 1,557,765,596 at 2020-03-31, from the cover of the [20-F filed 2020-06-24](/filings/0001395064-20-000110.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.